-+ 0.00%
-+ 0.00%
-+ 0.00%

Biohaven's BHV-1530 shows responses in 6 of 10 evaluable patients in Phase 1 cancer trial

PUBT·11/19/2026 12:33:13
Diffusion vocale
Biohaven's BHV-1530 shows responses in 6 of 10 evaluable patients in Phase 1 cancer trial
  • Biohaven presented Phase 1 results for BHV-1530 at ENA 2026, showing responses in FGFR3-altered urothelial and head and neck cancers.
  • Responses included previously treated patients whose cancers had progressed; all responders remained on treatment at the data cutoff, some beyond six months.
  • The investigational drug was well tolerated, with no dose-limiting toxicities or treatment-related serious adverse events or deaths.
  • Following FDA discussions, a pivotal trial could begin as early as the first half of 2027, initially targeting urothelial cancer for potential accelerated approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611190730PR_NEWS_USPR_____NE01891) on November 19, 2026, and is solely responsible for the information contained therein.